Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Here, Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, outlines the importance of regulation when a novel therapy such as CAR T-cell therapy is introduced, and what to expect from the regulatory session taking place on Day 2 of the 2nd European CAR T-cell Meeting in Sitges, Spain.
We use necessary cookies to make this site work. Analytics, preference, and marketing cookies are used only if you choose to allow them. You can change your choice at any time. For more information view our Cookie Policy.